Premium
Intravenous Captopril in Congestive Heart Failure
Author(s) -
Ahmad Safeer,
Giles Thomas D.,
Roffidal Louise E.,
Haney Yolanta,
Given Michael B.,
Sander Gary E.
Publication year - 1990
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1990.tb01863.x
Subject(s) - captopril , medicine , pulmonary wedge pressure , heart failure , cardiology , vascular resistance , hemodynamics , cardiac index , plasma renin activity , blood pressure , cardiac output , stroke volume , bolus (digestion) , pulmonary artery , mean arterial pressure , anesthesia , ejection fraction , heart rate , renin–angiotensin system
Hemodynamic and neurohumoral effects of intravenous captopril were studied in ten patients with severe chronic congestive heart failure (NYHA Functional Class III and IV). Incremental bolus doses of captopril, titrated to a maximum cumulative dose of 15 mg, were given at 10‐minute intervals. Systemic arterial pressure, mean pulmonary capillary wedge pressure, systemic vascular resistance, mean pulmonary artery pressure, and heart rate decreased ( P < .05). Cardiac index and stroke volume index increased ( P < .05). Maximum hemodynamic effects occurred after cumulative doses of 7 mg and were seen within 30 minutes after initiation of therapy; responses persisted for 30–90 minutes after the last dose. Plasma renin activity increased, and plasma atrial natriuretic factor concentration decreased. No adverse effects were observed with the use of intravenous captopril. Thus, intravenous captopril produces rapid and favorable hemodynamic improvement in advanced heart failure patients.